|[April 23, 2014]
Dr. Reddy's Announces the Launch of Fenofibrate Capsules, USP 43 mg and 130 mg
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has
launched Fenofibrate Capsules, USP 43 mg and 130 mg a therapeutic
equivalent generic version of ANTARA® (fenofibrate) capsules,
in the US market on April 22, 2014, approved by the United States Food &
Drug Administration (USFDA).
The ANTARA® (fenofibrate) capsules brand and generic had U.S.
sales of approximately $74 Million MAT for the most recent twelve months
ending in February 2014 according to IMS Health*.
Dr. Reddy's Fenofibrate capsules, USP 43 mg is available in bottle
counts of 30 and 130 mg are available in bottle counts of 30 and 90.
This press release includes forward-looking
statements, as defined in the U.S. Private Securities Litigation Reform
Act of 1995. We have based these forward-looking statements on our
current expectations and projections about future eents. Such
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results to differ materially. Such factors
include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the
market acceptance of and demand for our products, our growth and
expansion, technological change and our exposure to market risks. By
their nature, these expectations and projections are only estimates and
could be materially different from actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY)
is an integrated global pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through its
three businesses - Pharmaceutical Services and Active Ingredients,
Global Generics and Proprietary Products - Dr. Reddy's offers a
portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Major
therapeutic focus is on gastro-intestinal, cardiovascular, diabetology,
oncology, pain management and anti-infective. Major markets include
India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets. For more information, log on to: www.drreddys.com
ANTARA® is a registered trademark of LUPIN ATLANTIS HOLDINGS,
*IMS National Sales Perspectives: Retail and Non-Retail MAT February 2014
[ Back To TMCnet.com's Homepage ]